Diagnostic criteria for systemic lupus erythematosus: Has the time come?

Nature Reviews Rheumatology

Volumn 9, Issue 11, 2013, Pages 687-694

  Bertsias, George K ^a   Pamfil, Cristina ^b   Fanouriakis, Antonios ^a   Boumpas, Dimitrios T ^c  

^a UNIVERSITY OF CRETE   (Greece)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

CLINICAL FEATURE; DELAYED DIAGNOSIS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; HUMAN; IMMUNOLOGICAL PROCEDURES; ONSET AGE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOLOGIC TESTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; RHEUMATOLOGY; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84887175816     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.103     Document Type: Review

References (50)

1. Uttenthal, B. J., Layton, D. M., Vyse, T. J. & Schreiber, B. E. Clinical problem-solving. The wolf at the door. N. Engl. J. Med. 366, 2216-2221 (2012).
2. Alonso, M. D. et al. Late-onset systemic lupus erythematosus in Northwestern Spain: differences with early-onset systemic lupus erythematosus and literature review. Lupus 21, 1135-1148 (2012).
3. Pons-Estel, G. J., Alarcon, G. S., Scofield, L., Reinlib, L. & Cooper, G. S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 39, 257-268 (2010).
4. Kamphuis, S. & Silverman, E. D. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat. Rev. Rheumatol. 6, 538-546 (2010).
5. Uramoto, K. M. et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 42, 46-50 (1999). (Pubitemid 29042569)
6. Alonso, M. D. et al. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. Medicine (Baltimore) 90, 350-358 (2011).
7. Feldman, C. H. et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 65, 753-763 (2013).
8. Lerang, K., Gilboe, I., Garen, T., Thelle, D. S. & Gran, J. T. High incidence and prevalence of systemic lupus erythematosus in Norway. Lupus 21, 1362-1369 (2012).
9. Bresnihan, B. Outcome and survival in systemic lupus erythematosus. Ann. Rheum. Dis. 48, 443-445 (1989).
10. Rivest, C. et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J. Rheumatol. 27, 680-684 (2000). (Pubitemid 30151346)
11. Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 8, 197-209 (1999). (Pubitemid 29186838)
12. Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups. II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 41, 1173-1180 (1998). (Pubitemid 28313417)
13. Hiraki, L. T. et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 64, 2669-2676 (2012).
14. Cervera, R. et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72, 113-124 (1993). (Pubitemid 23097765)
15. Nossent, J. et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19, 949-956 (2010).
16. Cerovec, M., Anic, B., Padjen, I. & Cikes, N. Prevalence of the American College of Rheumatology classification criteria in a group of 162 systemic lupus erythematosus patients from Croatia. Croat. Med. J. 53, 149-154 (2012).
17. Cross, L. S., Aslam, A. & Misbah, S. A. Antinuclear antibody-negative lupus as a distinct diagnostic entity-does it no longer exist? QJM 97, 303-308 (2004). (Pubitemid 38659767)
18. Mosca, M., Tani, C. & Bombardieri, S. Defining undifferentiated connective tissue diseases: a challenge for rheumatologists. Lupus 17, 278-280 (2008). (Pubitemid 351655793)
19. Calvo-Alen, J. et al. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J. Rheumatol. 23, 469-475 (1996). (Pubitemid 26101588)
20. Nimelstein, S. H., Brody, S., McShane, D. & Holman, H. R. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 59, 239-248 (1980). (Pubitemid 10093114)
21. Gendi, N. S. et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum. 38, 259-266 (1995).
22. Cappelli, S. et al. "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin. Arthritis Rheum. 41, 589-598 (2012).
23. Amezcua-Guerra, L. M. et al. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. Arthritis Res. Ther. 8, R144 (2006).
24. Aringer, M. & Smolen, J. S. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin. Drug Saf. 7, 411-419 (2008).
25. Sjowall, C. et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J. Rheumatol. 35, 1994-2000 (2008).
26. Meroni, P. L. & Schur, P. H. ANA screening: an old test with new recommendations. Ann. Rheum. Dis. 69, 1420-1422 (2010).
27. Craig, W. Y. & Ledue, T. B. The antinuclear antibody assay: developing criteria for reflexive anti-dsDNA antibody testing in a laboratory setting. Clin. Chem. Lab. Med. 49, 1205-1211 (2011).
28. Compagno, M. et al. Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study. Scand. J. Rheumatol. http://dx.doi.org/10.3109/03009742.2013.765032.
29. Swaak, T. & Smeenk, R. Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). Ann. Rheum. Dis. 44, 245-251 (1985). (Pubitemid 15112838)
30. Danieli, M. G., Fraticelli, P., Salvi, A., Gabrielli, A. & Danieli, G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin. Rheumatol. 17, 195-201 (1998). (Pubitemid 28346367)
31. Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003). (Pubitemid 37255038)
32. Wandstrat, A. E. et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J. Autoimmun. 27, 153-160 (2006). (Pubitemid 46048594)
33. Mariz, H. A. et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 63, 191-200 (2011).
34. Ahearn, J. M., Liu, C. C., Kao, A. H. & Manzi, S. Biomarkers for systemic lupus erythematosus. Transl. Res. 159, 326-342 (2012).
35. Li, Q. Z. et al. Risk factors for ANA positivity in healthy persons. Arthritis Res. Ther. 13, R38 (2011).
36. Li, Q. Z. et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin. Exp. Immunol. 159, 281-291 (2010).
37. Braunstein, I., Klein, R., Okawa, J. & Werth, V. P. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br. J. Dermatol. 166, 971-975 (2012).
38. Sood, R., Wong, W., Gotlib, J., Jeng, M. & Zehnder, J. L. Gene expression and pathway analysis of immune thrombocytopenic purpura. Br. J. Haematol. 140, 99-103 (2008). (Pubitemid 350233251)
39. Feng, X. et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J. Neurol. Sci. 313, 48-53 (2012).
40. Mackay, M. et al. Molecular signatures in lupus: untangling infection from inflammation. Arthritis Rheum. 64, S1088 (2012).
41. Li, Q. Z. et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin. Exp. Immunol. 147, 60-70 (2007).
42. Silverman, G. J. et al. Genetic imprinting of autoantibody repertoires in systemic lupus erythematosus patients. Clin. Exp. Immunol. 153, 102-116 (2008). (Pubitemid 351809346)
43. Grimes, D. A. & Schulz, K. F. Refining clinical diagnosis with likelihood ratios. Lancet 365, 1500-1505 (2005). (Pubitemid 40591696)
44. Somers, E. C., Antonsen, S., Pedersen, L. & Sorensen, H. T. Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter? Ann. Rheum. Dis. 72, 525-529 (2013).
45. Kassirer, J. P. Teaching clinical reasoning: case-based and coached. Acad. Med. 85, 1118-1124 (2010).
46. Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271-1277 (1982). (Pubitemid 13221242)
47. Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).
48. Calvo-Alen, J. et al. Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center. Arthritis Rheum. 38, 1475-1484 (1995).
49. Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677-2686 (2012).
50. Alarcon, G. S., McGwin, G. Jr, Madger, L. & Petri, M. Comparing the ACR and the SLICC criteria for the classification of SLE patients using data from an existing multi-ethnic cohort. Arthritis Rheum. 64, S262 (2012).